Orthocell Limited
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
2
Ending by 2030
Jun 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 11, 2026The maintenance fee for Method for producing a collagen membrane and uses thereof (US 10,314,939) comes due Dec 11, 2026. Unpaid by Jun 11, 2027, it lapses early.
- 1 fee due Feb 4, 2027The maintenance fee for Method for producing a collagen membrane and uses thereof (US 9,096,688) comes due Feb 4, 2027. Unpaid by Aug 4, 2027, it lapses early.
- 1 fee due Jun 29, 2027The maintenance fee for Method of producing native components, such as growth factors or extracellular matrix proteins, through cell culturing of tissue samples for tissue repair (US 9,220,803) comes due Jun 29, 2027. Unpaid by Dec 29, 2027, it lapses early.
- 1 fee due Jul 7, 2027The maintenance fee for Collagen construct and method for producing the collagen construct (US 10,524,895) comes due Jul 7, 2027. Unpaid by Jan 7, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,985,408 | Tenocyte cell culturing method In force · From the USPTO record | In force | From the USPTO record | |
| US 9,220,803 | Method of producing native components, such as growth factors or extracellular matrix proteins, through cell culturing of tissue samples for tissue repair In force · From the USPTO record | In force | From the USPTO record | |
| US 9,096,688 | Method for producing a collagen membrane and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 10,888,638 | Method for producing a collagen membrane and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 12,226,548 | Method for treating a tissue defect with a collagen-containing membrane In force · From the USPTO record | In force | From the USPTO record | |
| US 10,314,939 | Method for producing a collagen membrane and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 10,524,895 | Collagen construct and method for producing the collagen construct In force · From the USPTO record | In force | From the USPTO record | |
| US 12,678,275 | Collagen Construct and Method for Producing the Collagen Construct In force · Low confidence | In force | Low confidence | |
| US 11,517,419 | Collagen construct and method for producing the collagen construct In force · From the USPTO record | In force | From the USPTO record | |
| US 12,329,366 | Medical procedure kit and a related method In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 12: 1 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending · 5 no status recorded